Could Targeting miRNA-142-5p Be a Therapeutic Strategy Against COVID-19 Through Activation of The Anti-Inflammatory Nrf2/Keap1 Pathway?
Medhat, E., Samir, M., Elmessiery, R., El-Din, S. (2022). Could Targeting miRNA-142-5p Be a Therapeutic Strategy Against COVID-19 Through Activation of The Anti-Inflammatory Nrf2/Keap1 Pathway?. EKB Journal Management System, 14(1), 175-186. doi: 10.21608/eajbsc.2022.225920
Engy Medhat; Mai Samir; Riem M. Elmessiery; Shimaa Saad El-Din. "Could Targeting miRNA-142-5p Be a Therapeutic Strategy Against COVID-19 Through Activation of The Anti-Inflammatory Nrf2/Keap1 Pathway?". EKB Journal Management System, 14, 1, 2022, 175-186. doi: 10.21608/eajbsc.2022.225920
Medhat, E., Samir, M., Elmessiery, R., El-Din, S. (2022). 'Could Targeting miRNA-142-5p Be a Therapeutic Strategy Against COVID-19 Through Activation of The Anti-Inflammatory Nrf2/Keap1 Pathway?', EKB Journal Management System, 14(1), pp. 175-186. doi: 10.21608/eajbsc.2022.225920
Medhat, E., Samir, M., Elmessiery, R., El-Din, S. Could Targeting miRNA-142-5p Be a Therapeutic Strategy Against COVID-19 Through Activation of The Anti-Inflammatory Nrf2/Keap1 Pathway?. EKB Journal Management System, 2022; 14(1): 175-186. doi: 10.21608/eajbsc.2022.225920